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Abstract
Background: Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker.
However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between
individuals. Personal characteristics that influence CA125 could be used to improve its performance as
screening biomarker.
Methods: We developed and validated linear and dichotomous (≥35 U/mL) circulating CA125 prediction models in
postmenopausal women without ovarian cancer who participated in one of five large population-based studies:
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 26,981), European Prospective Investigation
into Cancer and Nutrition (EPIC, n = 861), the Nurses’ Health Studies (NHS/NHSII, n = 81), and the New England Case
Control Study (NEC, n = 923). The prediction models were developed using stepwise regression in PLCO and validated
in EPIC, NHS/NHSII and NEC.
Result: The linear CA125 prediction model, which included age, race, body mass index (BMI), smoking status and
duration, parity, hysterectomy, age at menopause, and duration of hormone therapy (HT), explained 5% of the total
variance of CA125. The correlation between measured and predicted CA125 was comparable in PLCO testing dataset
(r = 0.18) and external validation datasets (r = 0.14). The dichotomous CA125 prediction model included age, race, BMI,
smoking status and duration, hysterectomy, time since menopause, and duration of HT with AUC of 0.64 in PLCO and
0.80 in validation dataset.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: nsasamoto@bwh.harvard.edu
1Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s
Hospital and Harvard Medical School, 221 Longwood Avenue, Boston, MA
02115, USA
Full list of author information is available at the end of the article
Sasamoto et al. Journal of Ovarian Research          (2019) 12:116 
https://doi.org/10.1186/s13048-019-0591-4
(Continued from previous page)
Conclusions: The linear prediction model explained a small portion of the total variability of CA125, suggesting the
need to identify novel predictors of CA125. The dichotomous prediction model showed moderate discriminatory
performance which validated well in independent dataset. Our dichotomous model could be valuable in identifying
healthy women who may have elevated CA125 levels, which may contribute to reducing false positive tests using
CA125 as screening biomarker.
Keywords: Ovarian cancer, Early detection, CA125, Prediction model, Postmenopausal
Background
Cancer antigen 125 (CA125) is a high molecular-weight
glycoprotein (MUC16) normally expressed on tissues de-
rived from the coelomic and Mullerian epithelial cells
and aberrantly expressed on a variety of cancers, includ-
ing breast, lung, leukemia, gastric, and ovarian cancer
[1–3]. CA125 levels are elevated in more than 80% of
ovarian cancer cases and have proven utility assessing
response to therapy and prognosis [4].
While CA125 remains the most promising biomarker
for ovarian cancer screening, results from two large ran-
domized trials comparing combined CA125 and transva-
ginal ultrasound (TVUS) to usual care did not show
significant improvement in overall survival in the
screened group [5, 6]. In the United Kingdom Collabora-
tive Trial of Ovarian Cancer Screening (UKCTOCS),
stage of ovarian cancer diagnosis was earlier in the
screened group, but there was no clinically significant
reduction in overall mortality [6]. The Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial (PLCO)
showed no difference in ovarian cancer mortality be-
tween women screened with CA125 and TVUS and nor-
mal clinical care [5].
CA125 has been limited as an ovarian cancer screen-
ing biomarker by low sensitivity and specificity in part
due to variation associated with differences in personal
characteristics, such as age, hormone use, and meno-
pausal status [6–10]. Identifying factors that influence
CA125 levels in healthy individuals could be used to cre-
ate personalized thresholds for CA125, thereby improv-
ing its performance as an ovarian cancer screening
biomarker. Here we developed and validated two predic-
tion models (linear and dichotomous) of circulating
CA125 levels among postmenopausal women without
ovarian cancer who had participated in one of five large
population-based studies.
Methods
Study population
PLCO
The Prostate, Lung, Colorectal and Ovarian Cancer
(PLCO) Screening Trial was designed to determine the ef-
ficacy of screening in reducing mortality from four men-
tioned cancers [11]. Briefly, from 1993 to 2001, 155,000
healthy subjects, including 78,214 women ages 55–74,
were recruited from 10 study sites across the U. S and ran-
domized to screening (the intervention arm) or usual care
(the control arm). Screening intervention consisted of
CA125 measurements and transvaginal ultrasound at
baseline and at each of six annual screenings. For the pur-
pose of this analysis, we used only the baseline CA125
measurements. Data on demographic and lifestyle factors
were collected by questionnaires administered at baseline.
Among a total of 78,214 participants, we excluded women
from the control arm (n = 34,304), as well as those with no
ovaries at baseline (n = 9658), a prior diagnosis of ovarian,
fallopian or peritoneal cancer (n = 1), missing CA125 mea-
surements at baseline (n = 5624), missing baseline ques-
tionnaire data (n = 51), a diagnosis of ovarian cancer or
loss to follow-up within 3 year from baseline (n = 535),
and those missing information on candidate predictor var-
iables of CA125 (n = 1060). After these exclusions, data
from 26,981 PLCO participants were available for this
analysis.
EPIC
The European Prospective Investigation into Cancer and
Nutrition (EPIC) study is a prospective cohort estab-
lished between 1992 to 2000 [12]. Briefly, 519,978 partic-
ipants, including 366,521 women, recruited from 23
research centers in 10 European countries, had com-
pleted questionnaires on lifestyle, medical and dietary
factors. Most participants (74%) provided a blood sample
at baseline. Within this cohort, a nested case-control
study of ovarian cancer was designed by matching each
ovarian case (n = 810) with up to four controls using in-
cidence density sampling [13]. Among 1939 available
controls, we defined postmenopausal women as those
who met one of the following criteria at the time of
blood draw: not on hormones and had not menstruated
in the year prior to blood draw; on hormones and age
50 or greater; age at last menstruation was missing and
age 50 or greater; had hysterectomy and age 50 or
greater at the time of blood draw [7]. We excluded pre-
menopausal women (n = 485), women whose meno-
pausal status could not be determined using the
algorithm above (n = 26), women without available
CA125 measurement (n = 12), and those missing
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information on candidate predictor variables of CA125
(total n = 555), leading to a total study population of 861
EPIC participants for this analysis.
NHS/NHSII
The Nurses’ Health Study (NHS) is a prospective cohort
established in 1976 when 121,700 registered nurses residing
in 11U.S. states were enrolled to investigate the long-term
health outcomes of various contraceptive methods in women
[14]. Nurses’ Health Study II (NHSII) is a prospective cohort
established in 1989 when 116,429 nurses residing in 14 states
were enrolled to study the association between oral contra-
ceptives, diet, and lifestyle factors and long-term outcomes
[15]. Participants answered baseline and biennial follow-up
questionnaires about a variety of lifestyle, reproductive and
medical characteristics. Blood samples were collected at two
time points both in NHS (1989–1990, 2000–2002) and
NHSII (1996–1999, 2010–2011). Among women with avail-
able blood samples, CA125 was measured in 152 NHS par-
ticipants and 50 NHSII participants with no evidence of
ovarian cancer, for a total of 202 women. We restricted to
postmenopausal women defined as not having menstrual
period within the past 12months at the time of blood draw.
We excluded premenopausal women (n= 47), those with un-
known menopausal status (n= 14), and those missing infor-
mation on candidate predictor variables of CA125 (n= 60),
resulting in a final dataset of 81 NHS/NHSII participants for
this analysis.
NEC
The New England Case Control Study (NEC) is a
population-based ovarian cancer case-control study that en-
rolled participants from New Hampshire and Eastern Massa-
chusetts over three study phases (1992–1997, 1998–2002,
2003–2008) [16]. Briefly, a total of 2075 epithelial ovarian
cancer cases and 2100 controls, frequency matched on age
and state of residence, participated. All the participants were
interviewed in person about lifestyle factors, and medical and
reproductive history. Over 95% of the study participants pro-
vided blood specimens at enrollment. Of 2100 controls, we
restricted to postmenopausal women defined as: not on hor-
mones and self-reported their menstruation had stopped or
were regularly bleeding because of menopausal hormone
use, were not menstruating because of hysterectomy or a
medical condition/treatment and age at blood draw was 50
or greater. We excluded premenopausal women (n= 885),
women without CA125 values (n= 95), and those missing in-
formation on candidate predictor variables of CA125 (n=
197), resulting in a total population of 923 healthy women
for this analysis.
CA125 predictor variables
Candidate predictors of CA125 were selected for this
analysis based on the previously published reports [6–
10]. These included age at blood draw, race, body mass
index (BMI, calculated by kg/m2), smoking status and
pack-years (calculated by number of packs of cigarettes
per day multiplied by the number of smoking years), age
at menarche, use of oral contraceptives (OC), parity,
ovarian cysts, self-reported endometriosis, hysterectomy,
age at menopause, time since menopause, hormone
therapy (HT) use and duration, family history of ovar-
ian cancer in first-degree relatives, and previous his-
tory of cancer.
We first developed the prediction models in PLCO
using the candidate predictors above and then harmo-
nized the selected final predictors across all studies so
the categorization of the variables matched the variables
in PLCO. Information on predictor variables listed above
were collected by questionnaire data in all five studies.
For PLCO, EPIC, and NEC, predictor variables and
blood samples were obtained at baseline. For NHS/
NHSII, age and weight were obtained from the question-
naire administered at the time of blood draw and other
predictor variables were obtained from the most recent
biennial questionnaire prior to the blood collection.
Smoking duration among current smokers and former
smokers was defined by pack-years among current and
former smokers respectively across all studies. Age at
menopause was defined as the self-reported age at the
last menstrual period in all studies. For women who had
a hysterectomy and were missing age at menopause, age
at menopause was excluded. Time since menopause was
calculated by subtracting age at menopause from age at
blood draw.
CA125 measurements
In PLCO, CA125 was measured using the CA-125II
radioimmunoassay (Centocor) with an upper limit of
normal (ULN) of 35 U/mL, described in detail elsewhere
[8]. The coefficients of variation (CV) were 4.1% at a
CA125 level of 52.7 U/mL, and 3.8% at a CA125 level of
106.5 U/mL [5]. In NEC and NHS/NHSII, CA125 was
measured using CA-125II radioimmunoassay (Centocor)
at the CERLab at Boston Children’s Hospital. The repro-
ducibility of the assay was evaluated by including five
blinded aliquots of a uniform quality control pool in
each of the 46 test batches (CV = 1%). In EPIC, CA125
was measured using a volume-effective highly sensitive
multiplex platform (Meso Scale Discovery, MSD) in the
Genital Tract Biology Laboratory at Brigham and
Women’s Hospital, with ULN of 55 U/mL. The CV for
unblinded quality controls samples on each assay plates
was 8.4% [13].
Statistical analysis
CA125 levels were log-transformed to achieve normality
in all of the analyses.
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Recalibration of CA125
To account for the differences in CA125 values measured
in CA125II and MSD assays, we used data from 534 NEC
participants, including 353 postmenopausal women, with
CA125 measured using both assays to build the recalibra-
tion model [17]. First, we built a regression model to ob-
tain the intercept and beta coefficient (i.e. log-transformed
CA125II assay value = intercept + beta*log-transformed
MSD assay values). Then, we applied the intercept and
beta coefficient values from this model to calculate the
predicted log-transformed CA125II assay values for all the
EPIC participants based on their MSD assay values. We
used the predicted CA125 values based on this model for
all EPIC participants in our analyses.
We calculated geometric means of CA125 values
across levels of predictor variables and assessed the
changes in CA125 values using percent change calcu-
lated as [exp (beta)-1] × 100 for a 1-unit change in the
predictor. In order to develop the prediction model for
continuous CA125 values, we randomly divided the
PLCO dataset into a training (n = 17,987) and testing
(n = 8994) dataset. Using the PLCO training dataset, we
first examined the most appropriate way to model all the
variables (continuous, categorical). For continuous vari-
ables including age, BMI, parity, and pack-years of
smoking we tested for linearity of the association using
restricted cubic splines [18]. For categorical variables we
used likelihood ratio test to compare nested models, and
Vuong test and Akaike information criterion for non-
nested models [19]. Based on these evaluations, we mod-
eled the candidate predictors as follows: age, BMI, and
pack-years of smoking were modeled as continuous
variables; race (white, non-white), smoking status (cat-
egorical, never, current, former), age at menarche (cat-
egorical, < 10 years, 10–11 years, 12–13 years, 14–15
years, ≥ 16 years), OC use (never, ever), parity (categor-
ical, 0, 1, 2, 3, 4, ≥5), history of ovarian cysts (no, yes),
history of endometriosis (no, yes), history of
hysterectomy (no, yes), age at menopause (categorical, <
40 years, 40–44 years, 45–49 years, 50–54 years, ≥55
years), HT use (never, ever), time since menopause (cat-
egorical, < 5 years, 5–9 years, 10–14 years, 15–19 years,
≥20 years), duration of HT use (categorical, ≤ 1 years, 2–
3 years, 4–5 years, 6–9 years, ≥10 years), family history of
ovarian cancer (no, yes), family history of breast cancer
(no, yes), and previous history of cancer (no, yes).
Prediction modeling
We developed and validated CA125 prediction models
(linear and dichotomous) in postmenopausal women
using five large population-based datasets (Fig. 1). We
developed the prediction model in PLCO and validated
the models in EPIC and in NHS/NHSII/NEC combined
dataset.
Linear model
The association between individual predictors and CA125
levels were examined in age-adjusted models using linear
regression in the entire PLCO dataset. Linear trend was
tested using the continuous value of the variables (i.e. age,
BMI, pack-years in current/former smokers, parity) or
using the midpoint of the categories (i.e. age at menarche,
duration of OC use, age at menopause, time since meno-
pause, duration of HT use). To develop a linear CA125
prediction model, we used variables associated with
CA125 at p-value < 0.05 in univariate analysis and per-
formed a stepwise selection using p-values of 0.15 as
model entry and retention criteria in the PLCO training
dataset. Next, we tested the performance of the linear pre-
diction model in PLCO testing dataset, EPIC and NHS/
NHSII/NEC datasets. Briefly, predicted CA125 values in
those three datasets were calculated using effect estimates
from the linear prediction model developed in the PLCO
training dataset and plotted against the measured CA125
values. Pearson correlation coefficient (r) was used to
Fig. 1 Scheme of development and validation of CA125 prediction models using five population-based studies. We developed and validated
linear and dichotomous CA125 prediction models using five population-based studies: Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial (PLCO), Nurses’ Health Studies (NHS/NHSII), New England Case Control Study (NEC), and European Prospective Investigation into Cancer and
Nutrition (EPIC)
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Table 1 Age-adjusted association between selected characteristics and CA125 levels in Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial (PLCO)
Age-adjusted model
Characteristics N (%) Mean CA125 (U/mL) a % change p-value
Age
< 60 years 9388 (35) 10.1 (10.0, 10.2) Ref Ref
60–64 years 8351 (31) 10.4 (10.3, 10.5) 3.6 <.0001
65–69 years 5814 (22) 10.7 (10.5, 10.8) 5.8 <.0001
≥70 years 3428 (13) 10.8 (10.6, 11.0) 7.1 <.0001
p-trend <.0001
Race
White 24,166 (90) 10.6 (10.5, 10.7) Ref Ref
Black 1340 (5) 8.0 (7.8, 8.3) −24 <.0001
Hispanic 368 (1) 9.2 (8.8, 9.7) −12.6 <.0001
Asian 922 (3) 10.0 (9.7, 10.3) −6.4 <.0001
Pacific Islander, Native American 185 (1) 9.2 (8.6, 9.9) −13.2 <.0001
Body mass index
≤ 18.5 kg/m2 283 (1) 11.4 (10.8, 12.1) 7 0.02
18.5 < −25 kg/m2 10,778 (40) 10.6 (10.5, 10.7) Ref Ref
25 < −30 kg/m2 9408 (35) 10.4 (10.3, 10.5) − 1.4 0.04
> 30 kg/m2 6512 (24) 10.0 (9.9, 10.1) −5.4 <.0001
p-trend <.0001
Smoking
Never 15,288 (57) 10.4 (10.4, 10.5) Ref Ref
Current 2471 (9) 9.3 (9.1, 9.4) −10.8 <.0001
Former 9222 (34) 10.7 (10.6, 10.8) 2.3 0.0004
Pack-years among current smokers
< 13 49 (2) 8.5 (7.4, 9.7) Ref Ref
13–30 717 (29) 9.1 (8.8, 9.5) 7.4 0.33
≥ 30 1705 (69) 9.3 (9.1, 9.5) 10.1 0.18
p-trend 0.003
Pack-years among former smokers
< 13 3370 (37) 10.5 (10.3, 10.7) Ref Ref
13–30 2765 (30) 10.5 (10.3, 10.7) −0.1 0.91
≥ 30 3087 (33) 10.9 (10.7, 11.1) 3.4 0.01
p-trend 0.003
Age at first menstrual period
< 10 years 388 (1) 9.8 (9.3, 10.3) −5.3 0.03
10–11 years 4870 (18) 10.3 (10.1, 10.4) −1.6 0.05
12–13 years 14,703 (54) 10.4 (10.4, 10.5) Ref Ref
14–15 years 5845 (22) 10.5 (10.4, 10.6) 0.1 0.85
≥ 16 years 1153 (4) 10.2 (10.0, 10.5) −2.2 0.15
p-trend 0.18
Oral contraceptive use
Never 12,249 (45) 10.4 (10.3, 10.5) Ref Ref
Ever 14,720 (55) 10.4 (10.3, 10.5) 1.0 0.11
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Table 1 Age-adjusted association between selected characteristics and CA125 levels in Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial (PLCO) (Continued)
Age-adjusted model
Characteristics N (%) Mean CA125 (U/mL) a % change p-value
Duration of oral contraceptive use among ever users
< 1 year 3892 (26) 10.3 (10.2, 10.5) Ref Ref
2–3 years 3046 (21) 10.2 (10.1, 10.4) −0.3 0.79
4–5 years 1989 (14) 10.2 (10.0, 10.4) −0.7 0.62
6–9 years 2450 (17) 10.3 (10.1, 10.5) 0.7 0.58
≥ 10 years 3315 (23) 10.6 (10.4, 10.8) 2.9 0.01
p-trend 0.01
Parity
0 2396 (9) 10.1 (9.9, 10.3) Ref Ref
1 1938 (7) 10.0 (9.8, 10.2) −0.9 0.54
2 6238 (23) 10.5 (10.3, 10.6) 4.1 0.001
3 6692 (25) 10.4 (10.3, 10.6) 3.6 0.003
4 4598 (17) 10.6 (10.4, 10.7) 4.2 0.001
≥ 5 5119 (19) 10.4 (10.3, 10.6) 2.6 0.03
p-trend 0.02
Benign ovarian cyst
No 23,561 (90) 10.4 (10.4, 10.5) Ref Ref
Yes 2689 (10) 10.2 (10.0, 10.4) −2.0 0.05
Endometriosis
No 24,587 (94) 10.4 (10.4, 10.5) Ref Ref
Yes 1610 (6) 10.2 (10.0, 10.4) −1.3 0.17
Hysterectomy
No 19,597 (73) 10.8 (10.7, 10.8) Ref Ref
Yes 7384 (27) 9.5 (9.4, 9.6) −11.9 <.0001
Age at last menstrual period
< 40 years 3655 (14) 9.4 (9.2, 9.5) −11.8 <.0001
40–44 years 3499 (13) 10.0 (9.8, 10.2) −6.6 <.0001
45–49 years 6092 (23) 10.4 (10.3, 10.5) −2.9 0.0002
50–54 years 10,448 (39) 10.7 (10.6, 10.8) Ref Ref
≥ 55 years 3287 (12) 11.2 (11.0, 11.4) 5.3 <.0001
p-trend <.0001
Time since menopause
< 5 years 3254 (12) 10.6 (10.5, 10.8) Ref Ref
5–9 years 5120 (19) 10.5 (10.4, 10.7) −4.9 <.0001
10–14 years 5826 (22) 10.5 (10.4, 10.6) −8.7 <.0001
15–19 years 6356 (24) 10.2 (10.1, 10.4) −12.9 <.0001
≥ 20 years 6425 (24) 10.2 (10.1, 10.4) −17.4 <.0001
p-trend <.0001
Hormone therapy use
Never 9493 (35) 10.2 (10.1, 10.3) Ref Ref
Ever 17,488 (65) 10.5 (10.4, 10.6) 3.9 <.0001
Duration of hormone therapy b
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evaluate the linear correlation between measured and pre-
dicted CA125 values.
Dichotomous model
The association between individual predictors and
CA125 levels ≥35 U/mL was examined in age-adjusted
models using logistic regression in the entire PLCO
dataset since there were only 435 participants with
CA125 levels > 35 U/mL. Then, we developed a multi-
variate prediction model for CA125 ≥ 35 U/mL. To de-
velop the final dichotomous CA125 prediction model,
we used variables associated with CA125 levels at p-
value ≤0.05 in the univariate analysis and performed a
stepwise selection using p-values of 0.15 as model entry
and retention criteria. Using variables selected in the
stepwise selection, we evaluated the area under the curve
(AUC) of receiver-operating-characteristic (ROC) curves
in PLCO and NHS/NHSII/NEC datasets. EPIC was not
included since only a single participant with data on all
predictors had recalibrated a CA125 value ≥35 U/mL.
All statistical analyses were performed using SAS ver-
sion 9.4 (SAS Institute Inc., Cary, NC).
Results
Baseline characteristics were mostly similar across study
populations, with CA125 averaging between 10 and 14
U/mL (Additional file 1: Table S1). Briefly, women were
in their early 60s on average, with average BMI around
26 kg/m2, and mostly white race (> 90%). Approximately
half of the participants reported ever smoking and most
participants were parous (90%).
Recalibration of CA125
We recalibrated the CA125 values in the EPIC partici-
pants using the model based on 534 NEC controls with
CA125 measurements on both CA125II and MSD as-
says. The measured CA125II assay values and the recali-
brated values calculated based on the recalibration
model in NEC were highly correlated with Pearson cor-
relation coefficient of 0.90 (95%CI: 0.88–0.91).
Linear model
First, we evaluated the association between candidate
predictors and continuous CA125 levels in 26,981 post-
menopausal women in PLCO. Older age at blood draw,
white race, lower BMI, former smoking status, shorter
duration of smoking among former smokers, older age
at first menstrual period, higher parity, having history of
benign ovarian cyst, no history of hysterectomy, older
age at last menstrual period, ever use and longer dur-
ation of hormone therapy, and shorter time since meno-
pause were associated with higher levels of CA125
(Table 1).
We used stepwise regression analysis in the PLCO
training dataset to develop the linear prediction
model using variables associated with CA125 levels at
p-value < 0.05 in univariate models (i.e. age, race,
BMI, smoking status, pack-years among current
smokers, pack-years among former smokers, age at
Table 1 Age-adjusted association between selected characteristics and CA125 levels in Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial (PLCO) (Continued)
Age-adjusted model
Characteristics N (%) Mean CA125 (U/mL) a % change p-value
≤ 1 year 3267 (19) 10.3 (10.1, 10.5) Ref Ref
2–3 years 2860 (16) 10.5 (10.3, 10.7) 2.9 0.03
4–5 years 2508 (14) 10.4 (10.2, 10.6) 2.3 0.08
6–9 years 3421 (20) 10.6 (10.5, 10.8) 4.3 0.001
≥ 10 years 5432 (31) 10.6 (10.4, 10.7) 1.8 0.11
p-trend 0.15
Family history of ovarian cancer
No 25,471 (96) 10.4 (10.3, 10.5) Ref Ref
Yes 1049 (4) 10.3 (10.0, 10.6) −0.8 0.59
Family history of breast cancer
No 22,682 (86) 10.4 (10.4, 10.5) Ref Ref
Yes 3837 (14) 10.3 (10.1, 10.5) −1.3 0.12
Previous history of cancer
No 25,250 (94) 10.4 (10.3, 10.4) Ref Ref
Yes 1731 (6) 10.7 (10.4, 10.9) 2.3 0.06
a Geometric mean (5th, 95th percentile)
b Among ever hormone therapy users
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first menstrual period, parity, hysterectomy, age at last
menstrual period, time since menopause, and ever use
and duration of HT use).
The linear prediction model included age, race, BMI,
smoking status, pack-years among current and former
smokers, parity, hysterectomy, age at last menstrual
period, and HT use and duration, which explained 5% of
the variability of log-transformed CA125 (Table 2). Al-
ternatively, when all significant predictors were included
in the model without variable selection process (which
consists of variables above plus age at first menstrual
period and time since menopause), the r-squared was
0.05, same as that of the linear model developed using
stepwise regression with fewer predictors. The associa-
tions between the selected predictors and CA125 levels
in the multivariate model were similar to those observed
in the univariate model. Next, we calculated the pre-
dicted log-transformed CA125 levels in the validation
datasets based on the regression coefficients in the
PLCO training dataset. In the PLCO testing dataset, the
Pearson correlation coefficient of the measured and the
predicted log-transformed CA125 was 0.18 (95%CI:
0.16–0.20) (Fig. 2a). In NHS/NHSII/NEC dataset, the
Pearson correlation coefficient of the measured and the
predicted log-transformed CA125 was 0.14 (95%CI:
0.08–0.20) (Fig. 2b) and in EPIC dataset it was 0.14
(95%CI: 0.07–0.20) (Fig. 2c), both similar to that in the
PLCO testing dataset.
Dichotomous model
We evaluated the association between candidate predic-
tors and having CA125 ≥ 35 U/mL in PLCO (Additional
file 1: Table S2). Older age at blood draw, white race,
lower BMI, greater pack-years among former smokers,
nulliparity, no history of hysterectomy, older age at last
menstrual period, longer duration of HT use and shorter
time since menopause was associated with having
CA125 levels ≥35 U/mL.
We used stepwise regression analysis using all of the
candidate predictors to develop the dichotomous predic-
tion model, which included age, race, BMI, smoking
status, pack-years among current and former smokers,
hysterectomy, time since menopause, and duration of HT
use, with an AUC of 0.64 (95%CI: 0.61–0.66) in PLCO
(Table 3, Fig. 3). When we applied the regression coeffi-
cients in the PLCO to the validation dataset, the AUC was
0.80 (95%CI: 0.73–0.87) in NHS/NHSII/NEC (Fig. 3).
We observed that ever HT use and longer duration
of use were positively associated with CA125 levels
both in the linear and dichotomous model. Since
women with a history of hysterectomy are more likely
to have taken estrogen-only HT and type of HT may
be differentially associated with CA125 levels, we con-
ducted a stratified analysis by history of hysterectomy.
However, we did not observe statistically significant
effect modification by history of hysterectomy (p-
interaction = 0.58; data not shown).
Discussion
We confirmed factors contributing to variations in
CA125 levels among postmenopausal women, including
Table 2 Linear CA125 prediction model in Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial (PLCO) training
dataset
Predictor % Change in CA125
levels c
p-value
Age a (per year) 0.5 < 0.0001
Race
White Ref Ref
Black −20.7 < 0.0001
Hispanic −12.0 < 0.0001
Asian −8.5 < 0.0001
Other −11.4 0.005
Body Mass Index b (per kg/m2) −0.4 < 0.0001
Smoking status
Never Ref Ref
Current −16.9 < 0.0001
Former 0.5 0.60
Pack-years among current smokers 0.2 0.001
Pack-years among former smokers 0.1 0.02
Parity (per child) 0.9 0.0001
Hysterectomy −11.2 < 0.0001
Age at last menstrual period
< 40 years −2.5 0.08
40–44 years −1.7 0.18
45–49 years −0.6 0.53
50–54 years Ref Ref
≥ 55 years 4.6 0.0001
Hormone therapy
Never Ref Ref
Ever 2.1 0.85
Duration of hormone therapy
0 years Ref Ref
≤ 1 year −0.04 0.99
2–3 years 1.7 0.88
4–5 years 1.7 0.88
6–9 years 2.4 0.83
≥ 10 years 4.2 0.71
R-square 0.05
aCentered at 62 years
bCentered at 25.9 kg/m2
cEstimate from multivariate model adjusted for all listed predictors
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age, BMI, race, smoking status and duration, age at first
menstrual period, parity, having benign ovarian cyst,
hysterectomy, age at last menstrual period, HT use and
duration, and time since menopause. Based on these fac-
tors, we developed and validated two prediction models
in postmenopausal women without ovarian cancer using
data from five large population-based studies. The final
linear CA125 prediction model explained little of the
total variation of CA125 values but showed similar per-
formance in the testing and external validation datasets.
The final dichotomous CA125 prediction model showed
moderate discriminatory performance and validated well
in the external validation dataset. Interestingly, age,
BMI, race, hysterectomy, and duration of HT use were
selected in both linear and dichotomous models, sug-
gesting that these factors are robust predictors of CA125
levels in postmenopausal women.
Studies have examined personal factors that influence
CA125 levels in healthy women in order to improve the
clinical utility in interpreting the biomarker levels [7–10,
20]. The significant predictors selected in our linear pre-
diction model were consistent with three prior studies
that evaluated predictors of CA125 in postmenopausal
women without ovarian cancer [7–9]. Older age at blood
draw, non-white race, current smoking status, younger
age at menopause, and history of hysterectomy were sig-
nificant predictors that were consistently associated with
lower CA125 levels across all of the studies that had in-
formation on these variables. Increased parity was also
consistently associated with higher CA125 levels in two
of the studies that assessed parity [7, 9]. HT use and lon-
ger duration were associated with higher CA125 levels
in our linear prediction model, but the results were
Fig. 2 Validation of the linear CA125 prediction model in three independent datasets. The measured and the predicted log-transformed CA125
were plotted and Pearson correlation coefficients (r) were calculated to evaluate the performance of the model in three datasets. a Prostate,
Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) testing dataset (b) Nurses’ Health Studies (NHS/NHSII), New England Case Control
Study (NEC) (c) European Prospective Investigation into Cancer and Nutrition (EPIC)
Table 3 Dichotomous CA125 prediction model in Prostate,
Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
Predictor Odds Ratio (95% CI)a
Age (per year) 1.04 (1.01–1.07)
Race
White Ref
Non-white 0.68 (0.47–0.99)
Body mass index (kg/m2) 0.95 (0.93–0.97)
Smoking
Never Ref
Current 0.72 (0.31–1.64)
Former 1.01 (0.78–1.31)
Pack-years among current smokers 1.00 (0.98–1.02)
Pack-years among former smokers 1.01 (1.00–1.01)
Hysterectomy
No Ref
Yes 0.54 (0.41–0.73)
Time since menopause
< 5 years Ref
5–9 years 0.76 (0.52–1.04)
10–14 years 0.70 (0.46–1.05)
15–19 years 0.83 (0.52–1.31)
≥ 20 years 0.96 (0.56–1.64)
Duration of HT use
Never users Ref
≤ 1 year 0.60 (0.41–0.87)
2–3 years 0.80 (0.55–1.15)
4–5 years 0.88 (0.60–1.29)
6–9 years 1.27 (0.94–1.71)
≥ 10 years 1.22 (0.94–1.58)
AUC 0.64 (0.61–0.66)
aMutually adjusted for all other predictors in this table
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mixed in the prior two studies that examined HT use [7,
8]. This could be due to the possible differences in asso-
ciation by type of HT (e.g. estrogen only, estrogen and
progesterone combined). If many of the hormone ther-
apies were cyclical hormone therapies using estrogen
and progesterone combined, these would result in prolif-
eration of the endometrium and withdrawal bleeding
which may possibly lead to increase in CA125 levels
compared to women who are not on hormonal therapy
and have no withdrawal bleeding, given that CA125 is
expressed in the endometrial tissue. Although we did
not observe significant effect modification of the HT as-
sociations by history of hysterectomy, given that women
with history of hysterectomy are more likely to be on es-
trogen only HT, lack of effect modification is difficult to
conclude since we were not able to evaluate the associ-
ation by type of HT use due to limited information on
type of HT. We did investigate former and current HT
use separately, although the effect estimates were similar
in these two subgroups and therefore we combined the
categories into an “ever” use category when including in
the final model.
In addition to examining individual predictors, we
evaluated and validated the performance of the multi-
variate linear CA125 prediction model. Although several
variables were significant predictors of CA125 in
postmenopausal women and our linear prediction model
was validated in independent datasets, the total variance
explained by the linear prediction model was only 5%,
suggesting that the known predictors may not be suffi-
cient in explaining the CA125 variation. This is further
supported by the observed lack of significant improve-
ment in the model performance even when including all
significant predictors in the model.
We also developed and validated a dichotomous pre-
diction model using the CA125 ≥ 35 U/mL threshold.
Only one prior study examined predictors of CA125 ≥
35 U/mL in postmenopausal women, with age, BMI and
hysterectomy being the only significant factors in the
multivariate model [8], which were consistent with our
findings. Our final dichotomous model additionally in-
cluded race, smoking status and duration, time since
menopause, and duration of HT use as significant pre-
dictors. Furthermore, our final dichotomous model
showed moderate discriminatory performance with nine
predictors which validated well in the independent data-
set, suggesting the robustness of the model.
The major strength of our study was the use of data
from five large population-based studies to develop and
conduct internal and external validation of circulating
CA125 prediction models in postmenopausal women
without ovarian cancer, resulting in robust prediction
Fig. 3 Development and validation of the dichotomous CA125 prediction model. Receiver Operating Characteristic (ROC) curves were plotted
and the Area Under the Curve (AUC) were calculated to assess the discriminatory performance of the dichotomous CA125 prediction model in
the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) (solid line) and Nurses’ Health Studies (NHS/NHSII) / New England Case
Control Study (NEC) (dashed line)
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models. However, there are two major limitations to the
study. Since we restricted the candidate predictors to
those that have been described previously in the litera-
ture, we may be lacking significant predictors which
have not been investigated to date. Given that the total
variance explained by our final linear model was 5%,
there may be other predictors of CA125, such as genetic
variants, common medications, or dietary factors, which
may explain more of the variability of CA125 in post-
menopausal women. Misclassification of CA125 levels in
the EPIC cohort is also a concern since CA125 was mea-
sured using a different assay in this study. However, the
recalibrated CA125 values based on the MSD assay
values were highly correlated with the measured CA125
values using the CA125II assays in NEC (r = 0.90). In
addition, the performance of the final linear model in
NHS/NHSII/NEC was similar to that in EPIC, suggest-
ing the high accuracy of the recalibration model.
Conclusion
In summary, we developed and validated models predicting
circulating CA125 in healthy postmenopausal women. The
dichotomous prediction model showed moderate discrimin-
atory performance which validated well in independent data-
set. However, the linear prediction model explained a small
portion of the total variability of CA125, suggesting the need
to identify novel predictors of CA125. While CA125 has
shown value in distinguishing malignant from benign pelvic
masses [21, 22], its value as a screening biomarker in the
general population has been limited by elevated levels
roughly 10% of women without cancer result, which could
lead to unnecessary interventions and psychological harms
[23]. Our dichotomous model could be used to identify
healthy women who may have CA125 levels greater than the
current clinical cutoff, which may contribute to reducing
false positive tests using CA125 as screening biomarker.
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